# SARS-CoV-2 Human Challenge Characterisation Study

> **NCT04865237** · NA · COMPLETED · sponsor: **Imperial College London** · enrollment: 36 (actual)

## Conditions studied

- Covid19
- SARS-CoV Infection
- Corona Virus Infection
- Coronavirus
- COVID-19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 Virus 1x10^1 TCID50
- **DRUG:** Remdesivir
- **BIOLOGICAL:** SARS-CoV-2 Virus 1x10^2 TCID50
- **BIOLOGICAL:** SARS-CoV-2 Virus 1x10^3 TCID50

## Key facts

- **NCT ID:** NCT04865237
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-06
- **Primary completion:** 2022-07-11
- **Final completion:** 2022-07-11
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-05-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04865237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04865237, "SARS-CoV-2 Human Challenge Characterisation Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04865237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*